SCHEMBL9716952

SCHEMBL9716952

CCCCCCCCOc1ccccc1/C=C/C(N)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.61
▸ MAPT P10636 5/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ NR1I2 O75469 1/20 0.61
▸ CHRM2 P08172 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ ADRA2A P08913 1/20 0.61
▸ OPRK1 P41145 1/20 0.61
▸ HTR2B P41595 1/20 0.61
▸ SLC6A3 Q01959 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.50
▸ NFE2L2 Q16236 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NLRP1 Q9C000 1/20 0.50
▸ TFEB P19484 1/20 0.49
▸ KDM4E B2RXH2 4/20 0.48
▸ AR P10275 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29857458 0.90 LMNA (0.60) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL10383307 0.87 KDM4E (0.65) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL4331860 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL9716933 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL9716995 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL9717006 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL242465 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL9402733 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL8092292 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2
SCHEMBL4331862 0.87 PTGER1 (0.59) LMNAMAPTMEN1NR1I2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992009561-A1 NEW AMIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-06-11 — — WO disclosed
Send feedback